SEC For	m 4																		
FORM 4 UNITE				STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See						UT OF CHANGES IN BENEFICIAL OWNERSHIP										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
				1 1100					Investment C										
1. Name and Address of Reporting Person [*] <u>CLARK IAN T</u>									ker or Trading euticals,]		(Ch	eck all applie X Directo	cable) r	10% Owner					
1	(Last) (First) (Middle) C/O OLEMA PHARMACEUTICALS, INC. 512 2ND STREET, 4TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 06/09/2021								Officer (give title Other (specify below) below)						
(Street) SAN FRANCISCO CA 94107					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)				action		2A. Deemed Execution Date, if any (Month/Day/Yea		3. Transacti Code (Ins	4. Securi	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) or 5. Amount o		6. Owner Form: Di (D) or Inc (I) (Instr.	rect c lirect E 4) C	7. Nature of Indirect Beneficial Ownership			
								Code V	Amount	(A) oi (D)	(A) or Dring Trans		ed ction(s) 3 and 4)			Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3, Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day)	ate, Ti	ransa ode (iction Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	ate	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly Dir or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				c	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$27.66	06/09/2021			A		21,520		(1)	06/08/2031	Common Stock	21,520	\$0	21,520		D			

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

<u>/s/ John B. Moriarty, Jr.,</u>	00/10/2021
Attorney-in-Fact	<u>06/10/2021</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.